Publications
External

CDC

ISIRV

MSU

AAAAI

ASV

 

Peer-reviewed papers & invited reviews

  1. York IA, Stevens J, Alymova IV. Influenza Virus N-linked Glycosylation and Innate Immunity. Biosci Rep. 2018 Dec 14. pii: BSR20171505.
  2. Sayedahmed EE, Kumari R, Shukla S, Hassan AO, Mohammed SI, York IA, Gangappa S, Sambhara S, Mittal SK. Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy. Vaccine. 2018 Oct 29;36(45):6744-6751.
  3. Liu F, Tzeng WP, Horner L, Kamal RP, Tatum HR, Blanchard EG, Xu X, York I, Tumpey TM, Katz JM, Lu X, Levine MZ. Influence of Immune Priming and Egg Adaptation in the Vaccine on Antibody Responses to Circulating A(H1N1)pdm09 Viruses After Influenza Vaccination in Adults. J Infect Dis. 2018 Oct 5;218(10):1571-1581.
  4. Guo Z, Wilson JR, York IA, Stevens J. Biosensor-based epitope mapping of antibodies targeting the hemagglutinin and neuraminidase of influenza A virus. J Immunol Methods. 2018 Oct;461:23-29.
  5. Sayedahmed EE, Hassan AO, Kumari R, Cao W, Gangappa S, York I, Sambhara S, Mittal SK. A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose. Mol Ther Methods Clin Dev. 2018 Jul 17;10:210-222.
  6. Alymova IV, McCullers JA, Kamal RP, Vogel P, Green AM, Gansebom S, York IA. Virulent PB1-F2 residues: effects on fitness of H1N1 influenza A virus in mice and changes during evolution of human influenza A viruses. Sci Rep. 2018 May 10;8(1):7474.
  7. Reber AJ, Music N, Kim JH, Gansebom S, Chen J, York I. Extensive T cell cross-reactivity between diverse seasonal influenza strains in the ferret model. Sci Rep. 2018 Apr 17;8(1):6112.
  8. Kamal RP, Alymova IV, York IA. Evolution and Virulence of Influenza A Virus Protein PB1-F2. Int J Mol Sci. 2017 Dec 29;19(1).
  9. Wilson JR, Belser JA, DaSilva J, Guo Z, Sun X, Gansebom S, Bai Y, Stark TJ, Chang J, Carney P, Levine MZ, Barnes J, Stevens J, Maines TR, Tumpey TM, York IA. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge. Virology. 2017 Nov;511:214-221.
  10. Hassan AO, Amen O, Sayedahmed EE, Vemula SV, Amoah S, York I, Gangappa S, Sambhara S, Mittal SK. Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses. PLoS One. 2017 Oct 12;12(10):e0186244.
  11. Kamal RP, Blanchfield K, Belser JA, Music N, Tzeng WP, Holiday C, Burroughs A, Sun X, Maines TR, Levine MZ, York IA. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies. J Virol. 2017 Sep 27;91(20).
  12. Sun X, Belser JA, Pulit-Penaloza JA, Creager HM, Guo Z, Jefferson SN, Liu F, York IA, Stevens J, Maines TR, Jernigan DB, Katz JM, Levine MZ, Tumpey TM. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets. Virology. 2017 Aug;508:164-169.
  13. Kumar A, Kim JH, Ranjan P, Metcalfe MG, Cao W, Mishina M, Gangappa S, Guo Z, Boyden ES, Zaki S, York I, García-Sastre A, Shaw M, Sambhara S. Influenza virus exploits tunneling nanotubes for cell-to-cell spread. Sci Rep. 2017 Jan 6;7:40360.
  14. Kim JH, Reber AJ, Kumar A, Ramos P, Sica G, Music N, Guo Z, Mishina M, Stevens J, York IA, Jacob J, Sambhara S. Non-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease. Sci Rep. 2016 Nov 16;6:37341.
  15. Wilson JR, Guo Z, Reber A, Kamal RP, Music N, Gansebom S, Bai Y, Levine M, Carney P, Tzeng WP, Stevens J, York IA. An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo. Antiviral Res. 2016 Nov;135:48-55.
  16. Alymova IV, York IA, Air GM, Cipollo JF, Gulati S, Baranovich T, Kumar A, Zeng H, Gansebom S, McCullers JA. Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence. Sci Rep. 2016
  17. Music N, Reber AJ, Kim JH, York IA. Peripheral Leukocyte Migration in Ferrets in Response to Infection with Seasonal Influenza Virus. PLoS One. 2016 Jun 17;11(6):e0157903.
  18. Cao W, Liepkalns JS, Kamal RP, Reber AJ, Kim JH, Hofstetter AR, Amoah S, Stevens J, Ranjan P, Gangappa S, York IA, Sambhara S. RIG-I ligand enhances the immunogenicity of recombinant H7HA protein. Cell Immunol. 2016 Jun-Jul;304-305:55-8.
  19. Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans. Zhong W, Liu F, Wilson JR, Holiday C, Li ZN, Bai Y, Tzeng WP, Stevens J, York IA, Levine MZ. Open Forum Infect Dis. 2016 May 18;3(2):ofw102.
  20. A highly immunogenic vaccine against A/H7N9 influenza virus. Cao W, Liepkalns JS, Hassan AO, Kamal RP, Hofstetter AR, Amoah S, Kim JH, Reber AJ, Stevens J, Katz JM, Gangappa S, York IA, Mittal SK, Sambhara S. Vaccine. 2016 Feb 3;34(6):744-9.
  21. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets. Music N, Reber AJ, Kim MC, York IA, Kang SM. Vaccine. 2016 Jan 20;34(4):466-473.
  22. Wilson JR, Guo Z, Tzeng WP, Garten RJ, Xiyan X, Blanchard EG, Blanchfield K, Stevens J, Katz JM, York IA. (2015) Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus. Virology. 485:252-62. doi: 10.1016/j.virol.2015.08.004.
  23. Kamal RP, Kumar A, Davis CT, Tzeng WP, Nguyen T, Donis RO, Katz JM, York IA. (2015) Emergence of Highly Pathogenic Avian Influenza A(H5N1) Virus PB1-F2 Variants and Their Virulence in BALB/c Mice. J Virol. 2015 Jun;89(11):5835-46. doi: 10.1128/JVI.03137-14.
  24. Hearn C, Preeyanon L, Hunt HD, York IA. (2014) An MHC class I immune evasion gene of Marek's disease virus. Virology. 475C:88-95. doi: 10.1016/j.virol.2014.11.008.
  25. Alymova IV, York IA, McCullers JA. (2014) Non-Avian Animal Reservoirs Present a Source of Influenza A PB1-F2 Proteins with Novel Virulence-Enhancing Markers. PLoS One. 9(11):e111603. doi: 10.1371/journal.pone.0111603.
  26. Blanchfield K, Kamal RP, Tzeng WP, Music N, Wilson JR, Stevens J, Lipatov AS, Katz JM, York IA. (2014) Recombinant influenza H7 hemagglutinins induce lower neutralizing antibody titers in mice than do seasonal hemagglutinins. Influenza Other Respir Viruses. doi: 10.1111/irv.12285.
  27. Kamal RP, Katz JM, York IA. (2014) Molecular Determinants of Influenza Virus Pathogenesis in Mice. Curr Top Microbiol Immunol. 385:243-74
  28. Music N, Reber AJ, Lipatov AS, Kamal RP, Blanchfield K, Wilson JR, Donis RO, Katz JM, York IA. (2014) Influenza vaccination accelerates recovery of ferrets from lymphopenia. PLoS One.9(6):e100926. doi: 10.1371/journal.pone.0100926.
  29. Wilson JR, Tzeng WP, Spesock A, Music N, Guo Z, Barrington R, Stevens J, Donis RO, Katz JM, York IA. (2014) Diversity of the murine antibody response targeting influenza A(H1N1pdm09) hemagglutinin. Virology. 458-459:114-24. doi: 10.1016/j.virol.2014.04.011.
  30. Shepard SS, Davis CT, Bahl J, Rivailler P, York IA, Donis RO. (2014) LABEL: fast and accurate lineage assignment with assessment of H5N1 and H9N2 influenza A hemagglutinins. PLoS One. 9(1):e86921. doi: 10.1371/journal.pone.0086921.
  31. Seregin SS, Rastall DP, Evnouchidou I, Aylsworth CF, Quiroga D, Kamal RP, Godbehere-Roosa S, Blum CF, York IA, Stratikos E, Amalfitano A. (2013) Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens. Autoimmunity. 46(8):497-508
  32. York I, Donis RO. (2013) The 2009 pandemic influenza virus: where did it come from, where is it now, and where is it going? Curr Top Microbiol Immunol. 370:241-57
  33. Nguyen T, Rivailler P, Davis CT, Hoa do T, Balish A, Dang NH, Jones J, Vui DT, Simpson N, Huong NT, Shu B, Loughlin R, Ferdinand K, Lindstrom SE, York IA, Klimov A, Donis RO. (2012) Evolution of highly pathogenic avian influenza (H5N1) virus populations in Vietnam between 2007 and 2010. Virology. Oct 25;432(2):405-16.
  34. Nguyen T, Rivailler P, Davis CT, Hoa do T, Balish A, Dang NH, Jones J, Vui DT, Simpson N, Huong NT, Shu B, Loughlin R, Ferdinand K, Lindstrom SE, York IA, Klimov A, Donis RO. (2012) Evolution of highly pathogenic avian influenza (H5N1) virus populations in Vietnam between 2007 and 2010. Virology.432(2):405-16
  35. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu X, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE, Donis RO. (2012) A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A. 109(11):4269-74
  36. Kincaid EZ, Che JW, York I, Escobar H, Reyes-Vargas E, Delgado JC, Welsh RM, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Rock KL. (2011) Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol. 13(2):129-35.
  37. Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, Davidson DJ, Donis RO. (2011) Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One. 6(10):e25333
  38. Spesock A, Malur M, Hossain MJ, Chen LM, Njaa BL, Davis CT, Lipatov AS, York IA, Krug RM, Donis RO. (2011)The virulence of 1997 H5N1 influenza viruses in the mouse model is increased by correcting a defect in their NS1 proteins. J Virol. 85(14):7048-58
  39. Nguyen TT, Chang SC, Evnouchidou I, York IA, Zikos C, Rock KL, Goldberg AL, Stratikos E, Stern LJ. (2011)Structural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1. Nat Struct Mol Biol. 18(5):604-13
  40. Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, Compans RW, York I, Kang SM, Donis RO. 2011. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol. 18(12):2010-7
  41. Evnouchidou I, Kamal RP, Seregin SS, Goto Y, Tsujimoto M, Hattori A, Voulgari PV, Drosos AA, Amalfitano A, York IA, Stratikos E. (2011)Cutting Edge: Coding single nucleotide polymorphisms of endoplasmic reticulum aminopeptidase 1 can affect antigenic peptide generation in vitro by influencing basic enzymatic properties of the enzyme. J Immunol. 186(4):1909-13
  42. Georgiadou D, Hearn A, Evnouchidou I, Chroni A, Leondiadis L, York IA, Rock KL, Stratikos E. (2010) Placental leucine aminopeptidase efficiently generates mature antigenic peptides in vitro but in patterns distinct from endoplasmic reticulum aminopeptidase 1. J Immunol. 185(3):1584-92
  43. Dang Y, Wang X, York IA, Zheng YH. (2010) Identification of a critical T[Q/D/E]x5ADx2[I/L] motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity. J Virol. 2010
  44. Hearn A, York IA, Bishop C., Rock KL (2010) Characterizing the Specificity and Cooperation of Aminopeptidases in the Cytosol and Endoplasmic Reticulum during MHC Class I Antigen Presentation. J. Immunol 184:4725-32.
  45. Dang Y, Davis RW, York IA, Zheng YH (2010) Identification of 81LGxGVxIxW89 and 171EDRWN175 domains from human immunodeficiency virus type 1 virus Vif that regulate APOBEC3G and APOBEC3F neutralization activity. J. Virol. 84:5741-50.
  46. Dang Y, Wang X, Zhou T, York IA, Zheng YH (2009) Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J Virol 83:8544-8552.
  47. Hearn A, York IA, Rock KL (2009) The Specificity of Trimming of MHC Class I-Presented Peptides in the Endoplasmic Reticulum. J Immunol 183:5526-5536.
  48. Kawahara M, York IA, Hearn A, Farfan D, Rock KL (2009) Analysis of the Role of Tripeptidyl Peptidase II in MHC Class I Antigen Presentation In Vivo. J Immunol 183:6069-6077.
  49. Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Neefjes JJ, Rock KL (2008) Puromycin-sensitive aminopeptidase limits MHC class I presentation in dendritic cells but does not affect CD8 T cell responses during viral infections. J Immunol 180:1704-1712.
  50. Towne CF, York IA, Watkin LB, Lazo JS, Rock KL (2007) Analysis of the role of bleomycin hydrolase in antigen presentation and the generation of CD8 T cell responses. J Immunol 178:6923-6930.
  51. York IA, Bhutani N, Zendzian S, Goldberg AL, Rock KL (2006) Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J Immunol 177:1434-1443.
  52. York IA, Brehm MA, Zendzian S, Towne CF, Rock KL (2006) Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc Natl Acad Sci U S A 103:9202-9207.
  53. Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Neefjes JJ, Rock KL (2005) Leucine aminopeptidase is not essential for trimming peptides in the cytosol or generating epitopes for MHC class I antigen presentation. J Immunol 175:6605-6614.
  54. York IA, Grant EP, Dahl AM, Rock KL (2005) A mutant cell with a novel defect in MHC class I quality control. J Immunol 174:6839-6846.
  55. Rock KL, York IA, Goldberg AL (2004) Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 5:670-677.
  56. York IA, Mo AX, Lemerise K, Zeng W, Shen Y, Abraham CR, Saric T, Goldberg AL, Rock KL (2003) The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 18:429-440.
  57. Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, Goldberg AL (2002) An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat Immunol 3:1169-176.
  58. York IA, Chang SC, Saric T, Keys JA, Favreau JM, Goldberg AL, Rock KL (2002) The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol 3:1177-184.
  59. Rock KL, York IA, Saric T, Goldberg AL (2002) Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 80:1-70.
  60. Russell HI, York IA, Rock KL, Monaco JJ (1999) Class II antigen processing defects in two H2d mouse cell lines are caused by point mutations in the H2-DMa gene. Eur J Immunol 29:905-11.
  61. York IA, Goldberg AL, Mo XY, Rock KL (1999) Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev 172:49-66.
  62. York IA, Rock KL (1996) Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 14:369-396.
  63. Tomazin R, Hill AB, Jugovic P, York I, van Endert P, Ploegh HL, Andrews DW, Johnson DC (1996) Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J 15:3256-3266.
  64. York IA (1996) Immune evasion strategies of the herpesviruses. Chem Biol 3:331-335.
  65. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, Johnson D (1995) Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411-415.
  66. York IA, Johnson DC (1995) in Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses, ed McFadden G (R.G. Landes Co, Austin, TX), pp 89-110.
  67. Levatte M, Weaver L, York I, Johnson D, Dekaban G (1995) Delivery of a foreign gene to sympathetic preganglionic neurons using recombinant herpes simplex virus. Neuroscience 66:737-750.
  68. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC (1994) A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77:525-535.
  69. York IA, Johnson DC (1993) Direct contact with herpes simplex virus-infected cells results in inhibition of lymphokine-activated killer cells because of cell-to-cell spread of virus. J Infect Dis 168:1127-1132.
  70. York IA, Thorsen J (1992) Evaluation of a subunit vaccine for bovine adenovirus type 3. Am J Vet Res 53:180-183.

 

.
Contact: web@iayork.com
"